- Key Dates: Abstract Status Notification and Embargo Release
- Abstract Submission and Withdrawal Deadlines
- Length of Abstracts
- Abstract Categories
- Disclosure of Chemical Structures
- Sponsor Regulations
Abstract Submission is now closed. No new submissions may be initiated. The abstract submitter will remain open in edit-only mode through 10:00 a.m. ET on Monday, November 20. Authors who began an abstract submission before the official deadline may log into the submission portal until that time to complete their abstract submissions. Abstract records that do not have a status of Complete by 10:00 a.m. ET on Monday, November 20 will be withdrawn and will not be sent to the Program Committee for evaluation.
The abstract submission portal will re-open on Monday, December 18, and will remain open until 11:59 p.m. ET on Monday, January 8, 2024, to accommodate the submission of clinical trial and late-breaking abstracts.
Key Dates: Abstract Status Notification and Embargo Release
- December 15, 2023: Status Notifications Sent for Regular Abstracts (submitted for November 16 deadline)
- January 25, 2024: Scheduling Information Sent for Regular Abstracts (submitted for November 16 deadline)
- February 12, 2024: Status Notifications and Scheduling Information Sent for Late-Breaking and Clinical Trials Abstracts (submitted for January 8 deadline)
- March 5, 2024: Titles and Text of Regular Abstracts Posted to Online Itinerary Planner (4:30 p.m. ET)
- March 5, 2024: Titles of Late-Breaking and Clinical Trial Abstracts Posted to Online Itinerary Planner (4:30 p.m. ET)
- April 5, 2024: Text of Late-Breaking and Clinical Trial Abstracts Posted to Online Itinerary Planner (3 p.m. ET)
IMPORTANT: PROFFERED PAPER PRESENTATION FORMAT
All proffered papers that are accepted for poster or oral presentation at the AACR Annual Meeting 2024 must be presented in person. Posters will not be presented in electronic format, and remote minisymposium presentations will not be permitted. Presenters who are unable to travel to San Diego to present their proffered paper in person will have the opportunity to designate a coauthor to serve as the presenter. If no coauthors are available to present the paper in person, the abstract must be withdrawn.
Presenters of proffered abstracts that have been selected for oral presentation in a minisymposium must agree to have their presentations recorded and made available to meeting registrants on the virtual meeting platform. Presenters who decline to have their minisymposium presentation recorded will be withdrawn from the session and reassigned to a poster session.
IMPORTANT: PUBLICATION OF ABSTRACTS IN CANCER RESEARCH
In previous years, abstracts accepted for presentation at the AACR Annual Meeting were published in an online-only Proceedings supplement to the AACR journal Cancer Research after the conclusion of the meeting. For the AACR Annual Meeting 2024, the Proceedings supplement will be published prior to the meeting in two parts. Part 1 of the online Proceedings (regular abstracts) will be published on Friday, March 22, and Part 2 (clinical trials and late-breaking abstracts) will be published on Friday, April 5. Revised Proceedings supplements containing the full text of embargoed abstracts as well as any late changes will be published in Cancer Research approximately one month after the meeting.
Once the abstracts are published in the journal, additional requests for edits and withdrawals cannot be processed. Therefore, abstract authors should carefully read their abstracts before submission to ensure that all authors are listed correctly and that the text is correct. All requests to withdraw or edit abstracts must be received by the following deadlines:
• Regular Abstracts (submitted by the November 16 deadline): 5 p.m. ET Friday, February 9, 2024
• Clinical Trials and Late-Breaking Abstracts (submitted by the January 8 deadline): 5 p.m. ET Friday, February 23, 2024
SPECIAL INTEREST SUBMISSIONS
The AACR encourages submission of abstracts in the following categories, which will be given special consideration for oral presentation at the AACR Annual Meeting 2024:
- Cancer Disparities and Inequities Research. This abstract subcategory is included in the Population Sciences (PS), Prevention, Early Detection, and Interception (PR), and Science and Health Policy (SHP) categories.
- Studies Using Data from AACR Project GENIE®. While there is no specific abstract category for abstracts that describe work using AACR Project GENIE®, you can have your abstract considered by selecting “AACR Project GENIE®” as one of your keywords during the submission process.
- Studies to be Presented by Patient Advocates. Patient Advocacy and Engagement is a subcategory included in Science and Health Policy (SHP). Patient advocates may submit work to this category or any other category and simply select “Advocacy” as one of the keywords to be considered for a session featuring patient advocates as presenting authors.
AACR ABSTRACT SUBMISSION SYSTEM
Authors must submit abstracts for presentation at the AACR Annual Meeting 2024 using the AACR Abstract Submission System, which will re-open on December 18 for clinical trial and late-breaking abstract submissions. Once the submitter has reopened, you can create, modify, and submit abstracts until the January 8, 2024, deadline for clinical trial and late-breaking abstracts. Complete instructions on the use of the AACR Abstract Submission System will be provided on the website.
RESPONSIBILITIES OF AUTHORS
By submitting an abstract for presentation at the AACR Annual Meeting, abstract authors agree and/or attest to the following:
- Support for Abstract/Verification of Authorship. All authors accept individual responsibility for the accuracy and integrity of statements in their abstract, and the submitting author is required to ensure that all authors have confirmed that all statements are an accurate reflection of the presented data and have agreed to the submission of the abstract and to their being listed as contributors prior to submission. The submitting author is also required to ensure that all relevant contributors to the abstract are included in the list of authors. Authors will be notified of their inclusion on an abstract via email.
- Sponsorship of Abstracts. The submitting author must provide the name of an AACR member who has agreed to sponsor the abstract, and the submitting author must attest that the permission of the member sponsor has been secured prior to initiating an abstract submission. Refer to the Abstract Sponsorship Regulations for more information.
- Transfer of Copyright. On behalf of all authors, the submitting author must assign and transfer copyright for the abstract to the AACR.
- Presentation of Abstracts. All proffered papers scheduled for presentation at the AACR Annual Meeting 2024 must be presented in person. The submitting author for each abstract must designate a presenter who agrees to register for the meeting and attend the corresponding session to discuss in detail the research presented in the published abstract. If the assigned presenter cannot attend the meeting, the authors are expected to designate a replacement or withdraw the abstract (see Proffered Paper Presentation Format above).
- Confirmation of No Prior Publication/Presentation. Authors who submit an abstract confirm that they have not previously published these data, that they have not previously presented them at a large national annual scientific meeting, and that they are not planning to present or publish them prior to the dates of the AACR Annual Meeting 2024.
Exceptions: Encore presentations are permitted for clinical trials abstracts that are submitted for the January 8, 2024, clinical trials deadline. Encore clinical trials presentations that have been presented solely in abstract form, including publication in conference proceedings. During the submission process, authors of encore clinical trials abstracts must provide the date and name of the meeting at which the original trial abstract was presented. Submissions must include significant additional data from the previous presentation (as determined by the AACR Clinical Trials Committee). Any other exceptions to this policy are at the discretion of AACR leadership.VIEW ENCORE GUIDELINES
CONTENT OF ABSTRACTS
Each abstract should contain (a) an introductory sentence indicating the purposes of the study; (b) a brief description of pertinent experimental procedures; (c) a summary of the new, unpublished data; and (d) a statement of the conclusions.
Please note: There is a 50-author limit per abstract.
Abstracts should be carefully proofread to avoid errors in the published literature. American spelling should be used throughout; for more information regarding American spelling, please refer to Scientific Style and Format: The CSE Manual for Authors, Editors, and Publishers, Eighth Edition (Council of Science Editors, 2014).
ABSTRACT CONTROL NUMBER AND ABSTRACT PRESENTATION NUMBER
An Abstract Control Number (e.g., 24-A-1234-AACR) will be assigned to each abstract submitted online and will be listed on all email correspondence regarding the abstract. Please refer to the Abstract Control Number in any abstract communications.
The Control Number is for internal reference only. If your abstract is accepted for presentation, it will be assigned a permanent Presentation Number that will be used to identify it in all online and print abstract materials. Please place the Presentation Number on your poster and use it in citations of your published abstract. Do not place the Control Number on your poster.
FINANCIAL RELATIONSHIPS OF COAUTHORS
Per ACCME regulations, the AACR must collect information on the financial relationships of all meeting presenters and abstract authors. You will be asked to disclose your financial relationships and the financial relationships of each of your coauthors. For more information on financial relationships, visit the Continuing Medical Education page.
SPONSOR PERMISSION AND INFORMATION
Each abstract must be sponsored by an AACR member. You must secure the permission of the sponsor before submitting the abstract. For details, refer to the Abstract Sponsorship Regulations.
LENGTH OF ABSTRACTS
The combined length of the abstract body, title, and tables may not exceed 2,600 characters, not including spaces and the author string. Tables count for 800 characters against the limit. Submission cannot be completed for abstracts that exceed this limit. The maximum size for tables is 15 cells x 25 cells.
ABSTRACT CATEGORY, SUBCATEGORY, AND SUBCLASSIFICATION
You must select a category, subcategory, and subclassification for your abstract.Download the Abstract Categories
DISCLOSURE OF CHEMICAL STRUCTURES
Updated November 10, 2023: At the time of abstract submission, the submitting author is required to state whether chemical compounds were used in the scientific work to generate the data in the proffered paper. Chemical compounds are defined as low-molecular-weight (generally <1000 g/mol) organic or inorganic molecules, peptides, or proteins/nucleic acids cocrystallized with low-molecular-weight molecules.
If chemical compounds were used, the corresponding author is further required to indicate whether the complete chemical structures of the compounds used will be disclosed at the time of presentation at the meeting. Chemical structures are not required to be included at the time of abstract submission; rather, an indication of the intent to disclose any such structures at the time of presentation is required.
The AACR Annual Meeting Program Committee will subsequently evaluate any information provided by the corresponding author and determine the acceptability of the proffered paper for presentation. Those who do not intend to disclose chemical structures may have their abstracts rejected for presentation; however, a limited number of these abstracts without chemical structures may be accepted for presentation if deemed to be of sufficient scientific merit.
Each abstract submitted must be accompanied by a US$75 abstract submission fee. The submission fee can be paid by credit card or check. The fee is nonrefundable regardless of the final disposition of the abstract.
Regular Abstract Deadline
The deadline for abstract submissions was Thursday, November 16, 2023.
NOTE: Submitting an abstract for presentation at the AACR Annual Meeting 2024 does not constitute registration for the meeting. Abstract presenters must register to attend the meeting.
Late-Breaking Abstract Deadline
The deadline for late-breaking abstracts is 11:59 p.m. U.S. ET, Monday, January 8, 2024. Abstracts detailing highly significant and timely findings in any area of cancer research that were not available at the time of the regular abstract deadline will be considered for presentation at the Annual Meeting. Only those abstracts that are deemed to be of high scientific priority will be accepted. Abstract submission fees and sponsorship regulations also apply to late-breaking abstracts.
Clinical Trials Abstract Deadline
The deadline for clinical trials abstracts (including placeholder abstracts) is 11:59 p.m. U.S. ET, Monday, January 8, 2024. Final data for placeholder abstracts are due Tuesday, February 6, 2024. Abstract submission fees and sponsorship regulations also apply to clinical trials abstracts.
DEADLINE FOR WITHDRAWAL OF ABSTRACTS
Requests to withdraw regular abstracts will be accepted through Friday, February 9, 2024. Requests to withdraw late-breaking or clinical trials abstracts will be accepted through Friday, February 23, 2024. Withdrawal requests must be sent by email to [email protected]. Withdrawal requests must include the Abstract Control Number and title as well as an explanation of the reason for withdrawal. Requests to edit or withdraw abstract cannot be processed after the deadlines.
Authors may consider submitting a manuscript based on their meeting abstract. Manuscripts submitted by the deadlines noted in the Journals FAQ can be considered for publication simultaneously with the AACR’s Annual Meeting, provided major revisions are not required. In addition, manuscripts can be considered for publication beyond the simultaneous opportunity. For more information on all publication opportunities in an AACR journal, please contact the AACR Publishing Division at [email protected].
PRESENTATION OF PROFFERED PAPERS AT THE AACR ANNUAL MEETING
Every proffered abstract that has been accepted for publication in the online Proceedings must have a corresponding in-person presentation at the meeting. Specifically, the author listed as the presenter for an accepted proffered paper must attend the corresponding session to discuss in detail the research outlined in the published abstract, according to the specific guidelines of the session. If, due to unforeseen circumstances, the designated presenter is unavailable to attend the session to present the paper, he or she must contact the AACR Scientific Programs Department to designate a coauthor to serve as the presenter. If no abstract authors are available to present the data, the presenter must withdraw the abstract immediately by contacting the AACR Scientific Programs Department at [email protected].
Failure to comply with these regulations pertaining to abstract presentation may result in actions including, but not limited to:
- The withdrawal of the abstract from the session
- The removal of the abstract from the online Proceedings
- The loss of future sponsorship privileges for the sponsor of the abstract
- The loss of future abstract submission/authorship privileges for the presenter of the abstract
ABSTRACT SPONSORSHIP REGULATIONS
Expanded Abstract Sponsorship Privileges for AACR Members
Members must be in good standing in order to sponsor and endorse abstracts for presentation (see below for details). To be in good standing for the November 16 regular abstract deadline, member dues must be paid in full through 2023. To be in good standing for the January 8 late-breaking and clinical trials abstract deadline, member dues must be paid in full through 2024. Associate, Honorary, and Emeritus Members are exempt from the payment of dues; therefore, this regulation does not apply to them.
- Each abstract submitted for presentation at the AACR Annual Meeting must be sponsored by an Active, Emeritus, Honorary, Affiliate, or Associate AACR Member in good standing (dues paid or eligibility recertified). (Student members are not eligible to sponsor an abstract.)
- An Active, Emeritus, or Honorary Member may sponsor an unlimited number of abstracts and may use his or her sponsorship privileges in two ways: (a) to sponsor abstracts
on which he or she is listed as an author, or (b) to sponsor abstracts submitted by colleagues on which he or she is not listed as an author.
- An Associate Member in good standing may sponsor one abstract for each submission deadline provided that (a) he or she is the presenter of the abstract, and (b) an Active, Emeritus, or Honorary Member in good standing endorses the work. Active, Emeritus, and Honorary Members may endorse an unlimited number of abstracts.
- An Affiliate Member in good standing may sponsor one abstract for each submission deadline provided that he or she is the presenter of the abstract. (Affiliate Members are not required to provide an endorser.)
- Permission to list an AACR member as a sponsor or endorser must be obtained prior to selecting the sponsor/endorser in the Online Abstract Submission System.
- The sponsor must verify the content, authenticity, and quality of the abstract. Sponsorship of an abstract implies support for the data and the interpretations contained therein.
Compliance with these regulations is the responsibility of the authors. Adherence to these rules will be strictly enforced. Violations will result in the rejection of the abstract by the Program Committee. Questions about abstract sponsors should be directed to [email protected].
MEMBERSHIP APPLICATION DEADLINES FOR ABSTRACT SPONSORSHIP
Nonmember individuals interested in joining the AACR and sponsoring an abstract for AACR Annual Meeting 2024 must submit an application for membership no later than November 10, 2023. Individuals interested in joining the AACR and sponsoring a clinical trial or late-breaking abstract must submit an application for membership no later than January 3, 2024. Membership questions may be directed to [email protected].
General abstract inquiries
Please direct any questions to [email protected].